CLAIMS

1. A combination comprising:

AZD5363, or a pharmaceutically acceptable salt thereof;

with ~~an androgen receptor signalling modulator selected from:~~

MDV-3100~~;~~

~~AZD3514;~~

~~abiraterone, or an ester prodrug thereof; and~~

~~bicalutamide;~~

~~or a pharmaceutically acceptable salt thereof~~.

~~2. A combination as claimed in claim 1, comprising AZD5363, or a pharmaceutically acceptable salt thereof; with an androgen receptor signalling modulator which is MDV-3100.~~

~~3. A combination as claimed in claim 1, comprising AZD5363, or a pharmaceutically acceptable salt thereof; with an androgen receptor signalling modulator which is abiraterone or abiraterone acetate; or a pharmaceutically acceptable salt thereof.~~

~~4. A combination as claimed in any one of claims 1 to 3, for use as a medicament.~~

~~5~~2. A combination as claimed in ~~any one of claims~~claim 1 ~~to 3~~, for use as a medicament in the treatment of cancer.

~~6~~3. A combination as claimed in claim ~~5~~ 2 wherein the cancer is prostate cancer.

~~7~~4. A combination as claimed in claim ~~5~~ 2 wherein the cancer is castrate-resistant prostate cancer.

~~8~~5. A kit comprising:

(a) AZD5363, or a pharmaceutically acceptable salt, in a first unit dosage form;

(b) MDV-3100 in a second unit dosage form;

(c) container means for containing said first and second dosage forms;

and optionally, instructions for use.

~~9. A kit comprising:~~

~~(a) AZD5363, or a pharmaceutically acceptable salt, in a first unit dosage form;~~

~~(b) abiraterone or abiraterone acetate; or a pharmaceutically acceptable salt thereof, in a second unit dosage form;~~

~~(c) container means for containing said first and second dosage forms;~~

~~and optionally, instructions for use.~~

~~10~~6. A kit according to claim ~~6 or 7~~ 5, wherein the kit is for use in the treatment of cancer.

~~11~~7. A kit according to claim ~~6 or 7~~ 6, wherein the kit is for use in the treatment of prostate cancer.

~~12~~8. A kit according to claim ~~10~~ 7, wherein the kit is for use in the treatment of castrate-resistant prostate cancer.

~~13~~9. ~~A~~ Use of a combination ~~treatment~~ comprising ~~the simultaneous, separate or sequential administration of an effective amount of:~~ AZD5363, or a pharmaceutically acceptable salt thereof, ~~optionally together with a pharmaceutically acceptable diluent or carrier;~~

and ~~an effective amount of~~ MDV-3100, ~~optionally together with a pharmaceutically acceptable diluent or carrier,~~

~~to a warm-blooded animal, such as a human, in need of such therapeutic treatment, for use in the treatment of cancer~~in the manufacture of a medicament for the treatment of cancer.

~~14. A combination treatment comprising the simultaneous, separate or sequential administration of an effective amount of: AZD5363, or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable diluent or carrier;~~

~~and an effective amount of abiraterone or abiraterone acetate, or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable diluent or carrier,~~

~~to a warm-blooded animal, such as a human, in need of such therapeutic treatment, for use in the treatment of cancer.~~

~~15~~10. The use ~~A combination treatment~~ as claimed in ~~claims 13 or 14~~claim 9, wherein the medicament is for the treatment of

prostate cancer.

~~16~~11. The ~~combination treatment~~ use as claimed in claim ~~13 or 14~~10 wherein the ~~cancer is~~ medicament is for the treatment of castrate-resistant prostate cancer.

~~17~~12. The ~~combination treatment~~ use as claimed in claim ~~13 or 14~~ 11 wherein the medicament is for the treatment of ~~cancer is~~ metastatic castrate-resistant prostate cancer.